Samplix has announced a €25 million first close, comprising €3 million in new capital and €22 million in shareholder convertible bonds. The Danish BioTech company says the financing will support efforts to scale antibody discovery. The round remains open, with a €30 million target.
What does the first close include?
The first close brings together two forms of financing, rather than a single stated cash investment. Samplix reported €3 million as new capital and €22 million as shareholder convertible bonds. Convertible bonds are debt that may convert into shares under terms set for the financing. The source does not state those terms, including any conversion price or timing.
WLanholding GmbH led the round, with participation from all major shareholders, according to the source. The company is described as a privately owned European investment firm. The source does not identify the participating shareholders or specify how much any participant contributed. Those details are therefore undisclosed in the available information.
How did Samplix reach this stage?
Samplix was founded in 2013 and is headquartered in Birkerød. Its stated focus is droplet microfluidics for functional single-cell analysis in the biopharmaceutical sector. Microfluidics handles very small fluid volumes in controlled channels, while single-cell analysis examines individual cells. The company’s approach is intended to make high-throughput cellular screening possible without specialised instrumentation.
Its Xdrop platform places living cells and assay reagents inside double-emulsion droplets. Each droplet serves as a small, self-contained setting in which researchers can observe cell behaviour. Samplix says the droplets work with standard flow cytometry and cell-sorting equipment. This compatibility is presented as a way to analyse and sort functional droplets at high throughput.
What does the platform support?
The source describes uses spanning antibody discovery, immunotherapy, cell line development, genomic editing and other functional single-cell research. It says both biopharmaceutical companies and academic research institutions use the platform. Samplix identifies screening cells against hard-to-target proteins, including proteins embedded in cell membranes, as a persistent early-stage drug development challenge. The material does not quantify the platform’s use or report customer numbers.
The announced financing is linked to the company’s plan to scale the platform and widen commercial adoption. Samplix also says it wants to deepen partnerships with biopharma and academia. The source gives no breakdown of planned spending between those activities. It also does not state how much of the first close is available as new capital after accounting for the convertible bonds.
What should readers watch for next?
Dr. Werner Lanthaler, founder and Managing Director of WLanholding GmbH, is due to join the Samplix Board of Directors within the next year. The source says he will work with the management team on the company’s next phase. It does not provide a specific appointment date or further details about his board responsibilities. The financing round remains open to additional investors against its €30 million target.
The next disclosed financing update could clarify whether the target is reached and whether other investors join. The terms governing the shareholder convertible bonds also remain unstated. Samplix has described intended commercial and platform expansion, but the source supplies no timeline or performance measures. Those details will help readers assess how the financing translates into operations.